Literature DB >> 687831

Plasma cell leukemia (PCL): A report on 15 patients.

R K Woodruff, J S Malpas, A M Paxton, T A Lister.   

Abstract

Fifteen patients presenting with plasma cell leukemia (PCL) are reported in detail. The clinicopathologic features of PCL differ from typical myeloma and resemble those of acute leukemia: patients with PCL have less bone disease but a much higher incidence of organomegaly and tissue infiltration as well as diffuse marrow involvement and more pronounced pancytopenia. One of the reported patients developed meningeal plasma cell leukemia and is reported in detail. Cytomorphologic assessment of PCL cells showed nuclear immaturity and obvious nuclear/cytoplasmic asynchrony. Despite the use of cytotoxic agents known to be effective in myeloma, the prognosis in PCL is poor, and the median survival of the reported patients was only 2 mo.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 687831

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Thirty patients with primary plasma cell leukemia: a single center experience.

Authors:  Milica Colović; Gradimir Janković; Nada Suvajdzić; Natasa Milić; Vesna Dordević; Snezana Janković
Journal:  Med Oncol       Date:  2007-10-10       Impact factor: 3.064

2.  Meningeal infiltration by non-myelomatous IgD-secreting plasma cell dyscrasias.

Authors:  M Yebra; L Manzano; A de la Torre; J Hornedo; F Albarran; J L Menéndez
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

Review 3.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

4.  Survival of twenty-two months in a patient with primary plasma cell leukaemia treated with melphalan and prednisolone.

Authors:  J D Walker; R S Kaczmarski
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

5.  Plasma cell leukemia with an unusual karyotype and prolonged survival following oral alkylating agent therapy.

Authors:  P H Wiernik; D Sciortino; E Paietta; P Papenhausen; N Ciobanu; M Roberts
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  Plasma cell leukemia with an unusual karyotype and prolonged survival with oral alkylating agent therapy.

Authors:  P H Wiernik; D Sciortino; E Paietta; P Papenhausen; N Ciobanu; M Roberts
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

7.  Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy.

Authors:  M C Kuo; L Y Shih
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

8.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 9.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 10.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.